For an updated version of this story please click here.
NEW YORK, Feb. 6 - Systems biology company Beyond Genomics is close to striking a research collaboration with DiaDexus, one person from each company told GenomeWeb.
It would be the second partnership for startup Beyond Genomics. The company's maiden deal was inked last May with Elan Pharmaceuticals to apply its systems biology techniques for Alzheimer's research.
It was not immediately clear whether this new collaboration would be like the Elan deal.
A source close to one of the companies said that DiaDexus, which uses genomic sequence data to develop diagnostic and therapeutic targets with a special focus on cancer, is unable to comment because it is in a silent period that precedes an IPO.
Officials from Beyond Genomics would not return telephone calls seeking comment.
Beyond Genomics aims to increase the current level of throughput achieved by existing technologies and combine this capability with the ability to generate genomics, proteomics, and metabolite data.
In its deal with Elan, Beyond Genomics got a $5 million equity investment in exchange for a two-year commitment to help the pharma giant find biomarkers and drug targets for Alzheimer's disease.
"In addition to providing clinical expertise and support for the program, Elan will grant the joint venture a non-exclusive license to an important animal model, a mouse strain which develops many of the features of the human disease," Stephen Ober, president of Cambridge, Mass.-based Beyond Genomics, said in May.
At the time, Elan Pharmaceuticals said it believed Beyond Genomics' technology could potentially help to uncover new proteins at play in Alzheimer's.